Drug recall · September 12, 2018
AvKARE Valsartan and Hydrochlorothiazide 160 mg/12.5 mg tablets recall
Why: CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
AvKARE Valsartan and Hydrochlorothiazide 160 mg/12.5 mg tablets, 90-count bottle, Rx Only, Manufactured for: AvKARE, Inc. Pulaski, TN 38478, NDC 42291-885-90
- Lots / codes
Lots: 17325 Exp. 09/2018; 17856 Exp. 09/2018; 18396 Exp. 09/2018; 18702 Exp. 02/2019; 19020 Exp. 02/2019; 19222 Exp. 02/2019; 20030 Exp. 04/2019; 20381 Exp. 04/2019
- Quantity
- 24796 bottles
- Company
- Avkare Incorporated, Pulaski, TN
- Distribution
- Nationwide
- Initiated
- July 18, 2018 · Voluntary: Firm initiated
- Classified
- September 6, 2018
- Reported
- September 12, 2018
- Ended
- May 7, 2020
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Recalled with it (same recall event)
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Hydrochlorothiazide
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.